27
Oct

Watertown, MA’s Syros Pharmaceuticals has banked a massive $53 million Series B to support its innovative approach to treating cancer, targeting the genetic switches responsible for tumor growth.

…read more

Source: Syros hauls in $53M to disrupt cancer’s genetic roots

    

0 No comments